How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Matt Blackman has 25+ years of experience as a financial writer and 11+ years of expertise as a research analyst; contributes to several publications. Fibonacci levels are horizontal lines on a ...
Together AI builds an agentic compiler to try and bring recursive self improvement capabilities to open source models.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
RXRX is trading in the middle of its 52-week range and below its 200-day simple moving average. Price change The price of RXRX shares has decreased $0.26 since the market last closed. This is a 7.24% ...
The last time I spoke about Recursion Pharmaceuticals (RXRX), it was with a Seeking Alpha article entitled "Recursion: "Hold" Rating Based On Initial REC-4881 FAP Treatment Data." With respect to this ...
Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi’s development pipeline, with phase 1 clinical study currently planned to begin in 2027 Salt Lake City, UT, Oct. 15 ...
For the past few days I’ve been testing an impressive open-weight AI coding model called Flint. It suggests that fully recursive self-improvement, or RSI—an exciting and controversial approach that ...
Recursive, an AI startup founded last year, is starting to live up to its name. The company, which is trying to build AI that can improve itself, released its first model, Flint, on Wednesday. Flint ...
For the quickest way to join, simply enter your email below and get access. We will send a confirmation and sign you up to our newsletter to keep you updated on all your gaming news.